My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 830

    1.

    Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

    Lim W, Dentali F, Eikelboom JW, Crowther MA.

    Ann Intern Med. 2006 May 2;144(9):673-84.PMID: 16670137 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.

    Nutescu EA, Spinler SA, Wittkowsky A, Dager WE.

    Ann Pharmacother. 2009 Jun;43(6):1064-83. Epub 2009 May 19. Review.PMID: 19458109 [PubMed - indexed for MEDLINE]Related articles

    3.

    Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.

    Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, Lee KA, Cook RJ.

    J Crit Care. 2005 Dec;20(4):357-63.PMID: 16310608 [PubMed - indexed for MEDLINE]Related articles

    4.

    Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.

    Cestac P, Bagheri H, Lapeyre-Mestre M, Sié P, Fouladi A, Maupas E, Léger P, Fontan B, Massip P, Montastruc JL.

    Drug Saf. 2003;26(3):197-207.PMID: 12580648 [PubMed - indexed for MEDLINE]Related articles

    5.

    Low molecular weight heparins in patients with renal insufficiency.

    Symes J.

    CANNT J. 2008 Apr-Jun;18(2):55-61. Review.PMID: 18669012 [PubMed - indexed for MEDLINE]Related articles

    6.

    Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.

    Clark NP.

    Thromb Res. 2008;123 Suppl 1:S58-61. Epub 2008 Sep 21. Review.PMID: 18809206 [PubMed - indexed for MEDLINE]Related articles

    7.

    Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.

    George-Phillips KL, Bungard TJ.

    Pharmacotherapy. 2006 Oct;26(10):1479-90. Review.PMID: 16999658 [PubMed - indexed for MEDLINE]Related articles

    8.

    Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.

    Collet JP, Montalescot G, Fine E, Golmard JL, Dalby M, Choussat R, Ankri A, Dumaine R, Lesty C, Vignolles N, Thomas D.

    J Am Coll Cardiol. 2003 Jan 1;41(1):8-14.PMID: 12570937 [PubMed - indexed for MEDLINE]Related articles

    9.

    Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

    Chande N, McDonald JW, Macdonald JK.

    Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006774. Review.PMID: 18425969 [PubMed - indexed for MEDLINE]Related articles

    10.

    Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.

    Kruse MW, Lee JJ.

    Am Heart J. 2004 Oct;148(4):582-9.PMID: 15459586 [PubMed - indexed for MEDLINE]Related articles

    11.

    Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.

    Levin A, Ben-Artzi M, Beckerman P, Haber G, Varon D, Ben-Yehuda A, Muszkat M.

    Drugs Aging. 2009;26(1):77-85. doi: 10.2165/0002512-200926010-00006.PMID: 19102516 [PubMed - indexed for MEDLINE]Related articles

    12.

    How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.

    Hammerstingl C, Omran H, Tripp C, Poetzsch B.

    Thromb Haemost. 2009 Feb;101(2):325-32.PMID: 19190817 [PubMed - indexed for MEDLINE]Related articles

    13.

    Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.

    Mahé I, Aghassarian M, Drouet L, Bal Dit-Sollier C, Lacut K, Heilmann JJ, Mottier D, Bergmann JF.

    Thromb Haemost. 2007 Apr;97(4):581-6.PMID: 17393021 [PubMed - indexed for MEDLINE]Related articles

    14.

    Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.

    Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D.

    Circulation. 2004 Jul 27;110(4):392-8. Epub 2004 Jul 12.PMID: 15249498 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

    Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

    Clin Ther. 2007 Nov;29(11):2395-405. Review.PMID: 18158080 [PubMed - indexed for MEDLINE]Related articles

    16.

    Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency.

    Stöbe J, Siegemund A, Achenbach H, Preiss C, Preiss R.

    Int J Clin Pharmacol Ther. 2006 Oct;44(10):455-65.PMID: 17063975 [PubMed - indexed for MEDLINE]Related articles

    17.

    Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.

    Ellison J, Thomson AJ, Conkie JA, McCall F, Walker D, Greer A.

    Thromb Haemost. 2001 Dec;86(6):1374-8.PMID: 11776302 [PubMed - indexed for MEDLINE]Related articles

    18.

    Low-molecular-weight heparin in patients with renal insufficiency.

    Schmid P, Fischer AG, Wuillemin WA.

    Swiss Med Wkly. 2009 Aug 8;139(31-32):438-52. Review.PMID: 19685350 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.

    Wilson SJ, Wilbur K, Burton E, Anderson DR.

    Haemostasis. 2001 Jan-Feb;31(1):42-8.PMID: 11408748 [PubMed - indexed for MEDLINE]Related articles

    20.

    Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.

    Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM; TIMI 11A Investigators.

    Am Heart J. 2002 May;143(5):753-9.PMID: 12040334 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity